WO2004030712A1 - Controlled release therapeutic wound dressings - Google Patents
Controlled release therapeutic wound dressings Download PDFInfo
- Publication number
- WO2004030712A1 WO2004030712A1 PCT/GB2003/004295 GB0304295W WO2004030712A1 WO 2004030712 A1 WO2004030712 A1 WO 2004030712A1 GB 0304295 W GB0304295 W GB 0304295W WO 2004030712 A1 WO2004030712 A1 WO 2004030712A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ala
- modified
- elastin
- elastase
- wound
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title description 3
- 230000001225 therapeutic effect Effects 0.000 title description 2
- 108010067372 Pancreatic elastase Proteins 0.000 claims abstract description 77
- 102000016387 Pancreatic elastase Human genes 0.000 claims abstract description 76
- 108010014258 Elastin Proteins 0.000 claims abstract description 75
- 102000016942 Elastin Human genes 0.000 claims abstract description 66
- 229920002549 elastin Polymers 0.000 claims abstract description 66
- 230000004888 barrier function Effects 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 18
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 17
- 239000012530 fluid Substances 0.000 claims abstract description 14
- 230000015556 catabolic process Effects 0.000 claims abstract description 12
- 238000006731 degradation reaction Methods 0.000 claims abstract description 12
- 208000027418 Wounds and injury Diseases 0.000 claims description 89
- 206010052428 Wound Diseases 0.000 claims description 88
- 238000003776 cleavage reaction Methods 0.000 claims description 30
- 230000007017 scission Effects 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 21
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 16
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 230000000845 anti-microbial effect Effects 0.000 claims description 11
- 102100033167 Elastin Human genes 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical group C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims description 6
- IOUPEELXVYPCPG-UHFFFAOYSA-N Valylglycine Chemical compound CC(C)C(N)C(=O)NCC(O)=O IOUPEELXVYPCPG-UHFFFAOYSA-N 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 5
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 claims description 5
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 5
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 4
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 claims description 4
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 4
- 102000004318 Matrilysin Human genes 0.000 claims description 3
- 108090000855 Matrilysin Proteins 0.000 claims description 3
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 claims description 2
- VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 claims description 2
- 101150101095 Mmp12 gene Proteins 0.000 claims description 2
- 206010048038 Wound infection Diseases 0.000 claims description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 108010079364 N-glycylalanine Proteins 0.000 claims 1
- 108010047495 alanylglycine Proteins 0.000 claims 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 claims 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims 1
- 239000010410 layer Substances 0.000 description 55
- 239000000463 material Substances 0.000 description 28
- 102000013382 Gelatinases Human genes 0.000 description 19
- 108010026132 Gelatinases Proteins 0.000 description 19
- 230000002745 absorbent Effects 0.000 description 19
- 239000002250 absorbent Substances 0.000 description 19
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 15
- 238000005354 coacervation Methods 0.000 description 8
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 8
- 239000000017 hydrogel Substances 0.000 description 8
- 239000004599 antimicrobial Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- -1 terramycins Natural products 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000084 colloidal system Substances 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- 108010028275 Leukocyte Elastase Proteins 0.000 description 5
- 102000016799 Leukocyte elastase Human genes 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000012790 adhesive layer Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 3
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- XLPJNCYCZORXHG-UHFFFAOYSA-N 1-morpholin-4-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCOCC1 XLPJNCYCZORXHG-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920005830 Polyurethane Foam Polymers 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 2
- OMNKZBIFPJNNIO-UHFFFAOYSA-N n-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=O)CC(C)(C)NC(=O)C=C OMNKZBIFPJNNIO-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000011496 polyurethane foam Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 2
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229920001567 vinyl ester resin Polymers 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920013641 bioerodible polymer Polymers 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 102000052502 human ELANE Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- WQVJHHACXVLGBL-GOVYWFKWSA-N polymyxin B1 Polymers N1C(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)CCCC[C@H](C)CC)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1CC1=CC=CC=C1 WQVJHHACXVLGBL-GOVYWFKWSA-N 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A61L2300/434—Inhibitors, antagonists of enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Definitions
- the present invention relates to wound dressing materials, and in particular to new materials for the controlled release of therapeutic agents into wounds.
- Wound healing is a complex dynamic process that results in the restoration of anatomic continuity and function; an ideally healed wound is one that has returned to normal anatomic structure, function and appearance.
- Chronically contaminated wounds all contain tissue bacterial flora. These bacteria may be indigenous to the patient or might be exogenous to the wound. Closure, or eventual healing of the wound is often based on a physician's ability to control the level of the bacterial flora.
- wounds such as venous ulcers, pressure sores and diabetic ulcers have a disordered wound healing metabolism even in the absence of infection.
- wound chronicity is associated with elevated levels of protease enzymes in the wound that interfere with the normal processes of tissue formation and destruction in the wound.
- antimicrobial wound dressings are known having a liquid permeable wound contacting layer, an intermediate absorbent layer and an outer, liquid-impervious backing layer, in which one or more of the layers contains an antimicrobial agent.
- EP-A-0599589 describes layered wound dressings having a wound contacting layer of a macromolecular hydrocolloid, an absorbent layer, and a continuous, microporous sheet intermediate the wound contacting layer and the absorbent layer.
- the absorbent layer contains a low molecular weight antimicrobial agent that can diffuse into the wound.
- WO-A-238097 describes wound dressings comprising a liquid-permeable top sheet having a wound facing surface and a back surface, and a hydrogel layer on the wound facing surface of the top sheet.
- the top sheet is adapted to block or restrict passage of liquid from the back surface to the wound facing surface.
- the hydrogel layer is an insoluble hydrogel adapted to maintain a moist wound healing environment at the wound surface.
- the hydrogel may contain therapeutic agents, such as antimicrobial agents, for sustained release into the wound.
- MMPs metalloproteinases
- certain MMPs include matrix gelatinases, stromelysins and collagenases.
- MMP2 the only enzymes currently known to degrade insoluble elastin (apart from elastases) are the 92- and 72-kDa (MMP2) gelatinases, MMP9 and matrilysin (Mecham, R.P., et al. (1997) J. Biol. Chem.
- Mecham et al With regard to cleavage sites of elastase and MMPs the reader is referred to Mecham et al. As discussed in Mecham et al. elastin is degraded by neutrophil elastase at sequences Gly/Ala/Val-Gly or Gly/Ala-Ala. Neutrophil elastase, in contrast to MMPs, is a serine protease and prefers non-bulky amino acids in its degradation sequences, and has a Gly or Ala in its P1 position (see Mecham et al. for discussion of the P1 position).
- sequences cleaved by MMP's are characteristically adjacent to hydrophilic aliphatic residues such as Leu and lie in elastin and MMPs typically have lie or Leu in its P1 position.
- MMPs typically have lie or Leu in its P1 position.
- Pro-Xaa-(Gly/Ala)-Leu/lle or pro-Xaa-Ala-Ala- Leu/lle are degraded by gelatinase (see Mecham et al.), which are again distinct from those degraded by elastase.
- Pro-Xaa-(Gly/Ala)-Val/Phe and pro-Xaa-Ala-Ala-Val/Phe are also degraded by gelatinase, although these sequences are not as susceptible to cleavage as Pro-Xaa-(Gly/Ala)-Leu/lle or pro-Xaa-Ala-Ala-Leu/lle.
- the present invention provides wound dressings which comprise modified elastin (including derivatives of elastin) that have been modified in such a way that they are less susceptible (and preferably no longer susceptible) to degradation by non- elastase proteases that may be found in the wound environment, and particularly in non-infected wound environments, such as metalloproteinases.
- modified recombinant elastin with the Pro-Xaa-(Gly/AIa)- Leu/IIe, Pro-Xaa-Ala-Ala-Leu/lle, Pro-Xaa-(Gly/AIa)-Val/Phe or Pro-Xaa-Ala-Ala- Val/Phe sequences modified in such a way that they are less susceptible (and preferably no longer susceptible) to degradation by a non-elastase protease.
- elastin which is less susceptible (and which is preferably no longer susceptible) to degradation by non-elastase proteases is provided by the present invention.
- elastin could be produced with additional elastase-sensitive regions which are selectively degraded by neutrophil elastase.
- elastin films or sheets can be designed to degrade with defined kinetics following elevation of elastase levels.
- a first aspect of the invention comprises a wound dressing comprising a therapeutic agent and a barrier layer for initially separating the therapeutic agent from a wound fluid when in use, wherein the barrier layer comprises, and preferably consists of, modified elastin wherein (i) the elastin has been modified so that it is less susceptible to degradation by one or more non-elastase protease found in wound fluid; or
- the non-elastase protease is a matrix metalloproteinase (e.g. preferably the 72kDa gelatinase (MMP2), the 92kDa gelatinase (MMP9), matrilysin or metalloelastase) or a serine protease.
- MMP2 72kDa gelatinase
- MMP9 92kDa gelatinase
- matrilysin or metalloelastase a serine protease
- elastase we include neutrophil elastase and bacterial elastases present in infected wounds.
- the elastase is human neutrophil elastase.
- the elastin has been modified so that it is less susceptible to degradation by one or more non-elastase proteases and has been modified so that there are additional elastase sensitive regions which are selectively degraded by elastase.
- Elastin is comprised of cross-linked tropoelastin monomers.
- the recombinant production of tropoelastins is well known in the art. See, for example, US 6,232,458, WO 99/03886 and WO 94/14958.
- the term "elastin” as used herein includes (but is not limited to) the elastin formed by the cross-linking of tropoelastin molecules obtainable by the methods described in US 6,232,458, WO 99/03886 and WO 94/14958.
- Various methods of cross-linking tropoelastin monomers are known in the art and include those methods described in US 6,232,458, WO 99/03886 and WO 94/14958, the contents of which are incorporated herein by reference.
- tropoelastin is intended to include tropoelastin "derivatives", “variants” etc. as described in US 6,232,458, WO 99/03886 and WO 94/14958 whilst the term “elastin” is intended to include elastin, “elastin-like material”, “elastin-like products” etc. as described in US 6,232,458, WO 99/03886 and WO 94/14958.
- the term “elastin” as used herein need not necessarily refer to 'full length' elastin but may include peptide sequences based on smaller portions of elastin.
- modified elastin we refer to elastin which has been modified so as to decrease its susceptiblity to cleavage by one or more non-elastase proteases (the non-elastase proteases may be acting singly or in combination - as noted below non-elastase proteases may act synergistically to degrade elastin) which may be found in the wound environment, and particularly in non-infected wound environments, or to elastin which has been modified to increase its susceptiblity to elastase by the provision of additional elastase sensitive regions which are selectively degraded by elastase.
- the modifications to the elastin should not be such that the properties of the resulting structure no longer resemble wild- type elastin.
- the modified sequences should ideally be chosen to avoid the creation of sequences which may be cleaved by another non-elastase protease (e.g. collagenases) found in the wound environment and, in particular, in non-infected wound environments.
- non-elastase protease e.g. collagenases
- Various prior art references disclose sequences cleaved by non-elastase proteases, see for example WO 00/64486. Further, Mecham et al. describes methods for identifying cleavage sites in addition to disclosing cleavage sites of various MMPs.
- sequences in the elastin which are susceptible to cleavage by non-elastase proteases found in the wound environment it is preferred that the sequences are modified in such a way that they are not susceptible to cleavage by any other non-elastase protease found in the wound environment.
- the elastin may be modified so that at least some of the Pro-Xaa-(Gly/Ala)-Leu/lle, Pro-Xaa- Ala-Ala-Leu/lle, Pro-Xaa-(Gly/Ala)-Val/Phe or Pro-Xaa-Ala-Ala-Val/Phe sequences are modified so that the sequences are less susceptible, and preferably no longer susceptible, to cleavage by a non-elastase protease, such as the 72 or 92kDa gelatinases.
- changing the Proline in Pro-Xaa-(Gly/Ala)-Leu/lle, Pro-Xaa-Ala-Ala- Leu/lle, Pro-Xaa-(Gly/Ala)-Val/Phe or Pro-Xaa-Ala-Ala-Val/Phe is another means of reducing the ability to be degraded by MMPs.
- the proline is substituted with phenylalanine.
- sequences can be modified using standard molecular biological recombinant DNA techniques.
- the sequences may, for example, be modified by amino acid deletions, insertions or substitutions.
- the substitutions, deletions or insertions may involve one or more amino acids.
- Techniques for the genetic manipulation of sequences will be well known to those skilled in the art and such techniques are explained fully in the literature. See, for example, Sambrook et al. Molecular Cloning; A Laboratory Manual, Third Edition (2001).
- electrophoresis could be used to ensure that a reduced number of small molecular weight peptides (and preferably no small molecular weight peptides) are produced by degradation when the non-elastase protease (or non-elastase proteases) is mixed with the new recombinant elastin.
- non-elastase proteases may act synergistically to degrade elastin, and since various non-elastase proteases will be present in the wound environment, it is preferred that the effect of a modification is assessed by subjecting the modified sequence to more than one non-elastase protease (e.g. 3, 4, or 5 non-elastase proteases).
- Pro-Xaa-Gly-Leu sequences Preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, of the Pro-Xaa-Gly-Leu sequences have been modified in such a way that they are less susceptible, and preferably no longer susceptible, to cleavage by the 92k Da gelatinase.
- Pro-Xaa-Gly-lle sequences Preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, of the Pro-Xaa-Gly-lle sequences have been modified in such a way that they are less susceptible, and preferably no longer susceptible, to cleavage by the 92k Da gelatinase.
- Pro-Xaa-Ala-Leu sequences Preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, of the Pro-Xaa-Ala-Leu sequences have been modified in such a way that they are less susceptible, and preferably no longer susceptible, to cleavage by the 92k Da gelatinase.
- Pro-Xaa-Ala-lle sequences Preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, of the Pro-Xaa-Ala-lle sequences have been modified in such a way that they are less susceptible, and preferably no longer susceptible, to cleavage by the 92k Da gelatinase.
- Pro-Xaa-Ala-Ala-Leu sequences Preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, of the Pro-Xaa-Ala-Ala-Leu sequences have been modified in such a way that they are less susceptible (e.g. to Pro-Xaa-Glu-Val-Leu), and preferably no longer susceptible (e.g. to Pro-Xaa-Glu-Val- Val), to cleavage by the 92k Da gelatinase.
- less susceptible e.g. to Pro-Xaa-Glu-Val-Leu
- no longer susceptible e.g. to Pro-Xaa-Glu-Val- Val
- Pro-Xaa-Ala-Ala-lle sequences Preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, of the Pro-Xaa-Ala-Ala-lle sequences have been modified in such a way that they are less susceptible, and preferably no longer susceptible, to cleavage by the 92k Da gelatinase.
- Pro-Xaa-Gly-Val sequences Preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, of the Pro-Xaa-Gly-Val sequences have been modified in such a way that they are less susceptible, and preferably no longer susceptible, to cleavage by the 92k Da gelatinase.
- Pro-Xaa-Gly-Phe sequences Preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, of the Pro-Xaa-Gly-Phe sequences have been modified in such a way that they are less susceptible, and preferably no longer susceptible, to cleavage by the 92k Da gelatinase.
- Pro-Xaa-Ala-Val sequences Preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, of the Pro-Xaa-Ala-Val sequences have been modified in such a way that they are less susceptible, and preferably no longer susceptible, to cleavage by the 92k Da gelatinase.
- Pro-Xaa-Ala-Phe sequences Preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, of the Pro-Xaa-Ala-Phe sequences have been modified in such a way that they are less susceptible, and preferably no longer susceptible, to cleavage by the 92k Da gelatinase.
- Pro-Xaa-Ala-Ala-Val sequences Preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, of the Pro-Xaa-Ala-Ala-Val sequences have been modified in such a way that they are less susceptible, and preferably no longer susceptible, to cleavage by the 92k Da gelatinase.
- Pro-Xaa-Ala-Ala-Phe sequences Preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, of the Pro-Xaa-Ala-Ala-Phe sequences have been modified in such a way that they are less susceptible, and preferably no longer susceptible, to cleavage by the 92k Da gelatinase.
- the elastin has been modified so that there are additional elastase-sensitive regions which are selectively degraded by elastase.
- the elastin contains additional Gly/Ala/Val-Gly or Gly/Ala-Ala sequences.
- elastase-sensitive regions which are "selectively degraded by elastase” we refer to sequences which are cleavable by elastase but which are not cleavable by non-elastase proteases that may be found in the wound environment, and particularly in non-infected wound environments.
- elastase-sensitive regions which are "selectively degraded by elastase” are not cleavable by proteases such as gelatinases, collagenases and metalloproteinases.
- the additional Gly/Ala/Val-Gly or Gly/Ala-Ala sequences should be chosen with regard to those sequences which are degraded by non-elastase proteases (eg MMPs) found in the wound environment, to ensure that the additional Gly/Ala/Val-Gly or Gly/Ala-Ala sequences are not also degraded by a non-elastase protease such as a MMP2 or MMP9.
- MMPs non-elastase proteases
- Pro-Xaa-Gly-lle was modified by replacement of lie with Gly this would not only result in a sequence with reduced susceptibility to cleavage by a non-elastase protease but would also result in a sequence which is susceptible to elastase cleavage.
- a sequence susceptible to cleavage by a non-elastase protease is modified to render it less susceptible to cleavage by a non-elastase protease but more susceptible to cleavage by elastase.
- the elastin has been modified so as to increase the number of elastase-sensitive regions which are selectively degraded by elastase by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200% or 250%.
- the elastin has been modified so as to increase the number of Ala-Gly sequences by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200% or 250%.
- the elastin has been modified so as to increase the number of Val-Gly sequences by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200% or 250%.
- the elastin has been modified so as to increase the number of Ala-Ala sequences by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200% or 250%.
- the elastin has been modified so as to increase the number of Gly-Ala sequences by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200% or 250%.
- the therapeutic agent may be selected from the group consisting of antimicrobial substances, pain relieving substances, protease inhibitors, and mixtures thereof.
- the wound dressing comprises an antimicrobial substance.
- the antimicrobial agent may, for example, comprise an antiseptic, an antibiotic, or mixtures thereof.
- Preferred antibiotics include tetracycline, penicillins, terramycins, erythromycin, bacitracin, neomycin, polymycin B, mupirocin, clindamycin and mixtures thereof.
- Preferred antiseptics include silver sulfadiazine, chlorhexidine, povidone iodine, triclosan, other silver salts, sucralfate, quaternary ammonium salts and mixtures thereof.
- the pain relieving agent may be an analgesic or a local anaesthetic.
- the barrier layer is separate from the therapeutic agent, and the therapeutic agent is initially prevented from contacting the wound fluid by the barrier layer. That is to say, the bioavailability of the therapeutic agent to the wound surface is low until the barrier material has been broken down by elastase, at which point the bioavailability increases sharply. Since elastase levels are elevated in infected wounds, this provides for accelerated or selective release of the therapeutic agent into such wounds.
- the barrier layer is normally substantially impervious to wound fluid and insoluble therein unless the wound fluid contains a sufficient level of elastase enzyme to break down the substrate material.
- the barrier layer is preferably about 0.1 to about 3 mm thick. Preferably about 0.5 to 1.5 mm thick.
- the modified elastin material may be combined in a film-forming composition with additional polymeric materials, plasticisers, and humectants. Suitable polymers include alginates, guar gum, carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, locust bean gum, carrageenan, chitosan, heparan sulfate, dermatan sulfate, glycosaminoglycans such as hyaluronic acid, proteoglycans, and mixtures thereof.
- Suitable plasticisers include C2-C8 polyhydric alcohols such as glycerol.
- modified elastin material makes up at least about 10%, 15%, 20%, 25%, 30% or 35% by weight of the film- forming composition.
- the barrier layer comprises a substantially continuous film comprising the film forming composition of the modified elastin material as described above.
- the barrier layer comprises an apertured sheet having a composition comprising the substrate material applied thereto in occlusive fashion.
- the occlusive composition may be similar to the film-forming composition described above.
- the apertures typically make up from about 0.1 % to about 50% of the area of the wound facing surface of the sheet before swelling, more typically from about 1 % to about 30% of the area of the apertured sheet, and preferably from about 10% to about 25% of the area of the apertured sheet.
- the apertured sheet has from about 1 to about 30 apertures per square cm, for example from about 4 to about 15 apertures per square cm or from about 5 to about 10 apertures per square cm.
- the apertures are uniformly distributed over the surface of the sheet, preferably in a regular pattern.
- each aperture may for example be from about 0.01 to about 10 mm 2 , preferably from about 0.1 to about 4 mm 2 , and more preferably from about 1mm 2 to about 2mm 2 .
- the sheet may include more than one size and shape of aperture in order to provide apertures that open more or less quickly on exposure to infected wound fluid. This enables still more control over the dynamics of therapeutic agent delivery to the wound.
- substantially the whole area of the apertures in the apertured sheet is blocked by the barrier material before exposure to wound exudate
- the thickness of the barrier film or the apertured sheet (by ASTM D374- 79) is from about 0.2 to about 5 mm, more preferably from about 0.4 to about 3 mm.
- the barrier layer material may further comprise a polymer selected from the group consisting of water soluble macromolecular materials (hydrogels) such as sodium alginate, sodium hyaluronate, alginate derivatives such as the propylene glycol alginate described in EP-A-0613692, and soluble hydropolymers formed from vinyl alcohols, vinyl esters, vinyl ethers and carboxy vinyl monomers, meth(acrylic) acid, acrylamide, N-vinyl pyrrolidone, acylamidopropane sulphonic acid, PLURONIC (Registered Trade Mark) (block polyethylene glycol, block polypropylene glycol) polystyrene-, maleic acid, NN-dimethylacrylamide diacetone acrylamide, acryloyl morpholine, and mixtures thereof.
- Suitable hydrogels are also described in US-A-5352508.
- the barrier layer material may further comprise a polymer selected from the group consisting of bioerodible polymers such as polylactide/polyglycolide, collagen, gelatin, polyacrylate gels such as those described in EP-A-0676457, calcium alginate gels, cross-linked hyaluronate gels, gels of alginate derivatives such as propylene glycol alginate, and gels wherein the hydropolymer is formed from vinyl alcohols, vinyl esters, vinyl ethers and carboxy vinyl monomers, meth(acrylic) acid, acrylamide, N-vinyl pyrrolidone, acylamidopropane sulphonic acid, PLURONIC (Registered Trade Mark) (block polyethylene glycol, block polypropylene glycol) polystyrene-, maleic acid, NN-dimethylacrylamide diacetone acrylamide, acryloyl morpholine, and mixtures thereof.
- bioerodible polymers such as polylactide/
- the barrier layer material may further comprise from about 5 to about 50% by weight, preferably from 15 to 40% by weight, on the same basis of one or more humectants such as glycerol.
- the barrier layer material may further contain up to about 30% w/w, more preferably up to about 15% w/w on the same basis of water.
- wound dressings have a layered structure wherein preferably a layer of the antimicrobial substance is provided behind the barrier layer. That is to say, on the side of the barrier layer opposite to the wound facing surface of the barrier layer in use.
- the layer of antimicrobial substance may contact the barrier layer directly, or may be separated therefrom for example by an absorbent layer.
- the barrier sheet according to these embodiments of the invention forms part of a layered wound dressing having the antimicrobial material disposed on the side of the barrier sheet opposite to the wound facing side of the barrier sheet.
- the layered wound dressing further comprises an absorbent layer or a backing layer.
- the area of the optional absorbent layer is typically in the range of from 1cm 2 to 200cm 2 , more preferably from 4cm 2 to 100cm 2 .
- the optional absorbent layer may be any of the layers conventionally used for absorbing wound fluids, serum or blood in the wound healing art, including gauzes, nonwoven fabrics, superabsorbents, hydrogels and mixtures thereof.
- the absorbent layer comprises a layer of absorbent foam, such as an open celled hydrophilic polyurethane foam prepared in accordance with EP-A-
- the absorbent layer may be a nonwoven fibrous web, for example a carded web of viscose staple fibers.
- the basis weight of the absorbent layer may be in the range of 50-500g/m 2 , such as 100-400g/m 2 .
- the uncompressed thickness of the absorbent layer may be in the range of from
- the dressing further comprises a backing layer covering the barrier sheet and the optional absorbent layer on the side opposite the wound-facing side of the dressing.
- the backing layer preferably provides a barrier to passage of microorganisms through the dressing and further preferably blocks the escape of wound fluid from the dressing.
- the backing layer may extend beyond at least one edge of the barrier sheet and optional absorbent layer to provide an adhesive- coated margin adjacent to the said edge for adhering the dressing to a surface, such as to the skin of a patient adjacent to the wound being treated.
- An adhesive- coated margin may extend around all sides of the barrier sheet and optional absorbent layer, so that the dressing is a so-called island dressing. However, it is not necessary for there to be any adhesive-coated margin.
- the backing layer is substantially liquid-impermeable.
- the backing sheet is preferably semipermeable. That is to say, the backing sheet is preferably permeable to water vapour, but not permeable to liquid water or wound exudate.
- the backing sheet is also microorganism-impermeable.
- Suitable continuous conformable backing sheets will preferably have a moisture vapor transmission rate (MVTR) of the backing sheet alone of 300 to 5000 g/m 2 /24hrs, preferably 500 to 2000 g/m 2 /24hrs at 37.5 °C at 100% to 10% relative humidity difference.
- the backing sheet thickness is preferably in the range of 10 to 1000 micrometers, more preferably 100 to 500 micrometers.
- Suitable polymers for forming the backing sheet include polyurethanes and poly alkoxyalkyl acrylates and methacrylates such as those disclosed in GB-A- 1280631.
- the backing sheet comprises a continuous layer of a high density blocked polyurethane foam that is predominantly closed-cell.
- a suitable backing sheet material is the polyurethane film available under the Registered Trade Mark ESTANE 5714F.
- the adhesive layer should be moisture vapor transmitting or patterned to allow passage of water vapor therethrough.
- the adhesive layer is preferably a continuous moisture vapor transmitting, pressure-sensitive adhesive layer of the type conventionally used for island-type wound dressings, for example, a pressure sensitive adhesive based on acrylate ester copolymers, polyvinyl ethyl ether and polyurethane as described for example in GB-A-1280631.
- the basis weight of the adhesive layer is preferably 20 to 250 g/m 2 , and more preferably 50 to 150 g/m 2 . Polyurethane-based pressure sensitive adhesives are preferred.
- the adhesive layer extends outwardly from the absorbent layer and the envelope to form an adhesive-coated margin on the backing sheet around the absorbent layer as in a conventional island dressing.
- the barrier layer substantially encapsulates the antimicrobial substance.
- the dressing may comprise, or consist essentially of, particles such as microspheres of antimicrobial material encapsulated in a layer comprising the substrate material.
- the particles are preferably loaded with from 1 to 90 wt.%, more preferably from 3 to 50 wt.% of the antimicrobial agents.
- the particles may be made by any suitable technique, including comminution, coacervation, or two-phase systems for example as described in US-A-3886084. Techniques for the preparation of medicated microspheres for drug delivery are reviewed, for example, in Polymeric Nanoparticles and Microspheres, Guiot and Couvreur eds., CRC Press (1986).
- a preferred method for preparation of the microparticles is coacervation, which is especially suited to the formation of particles in the preferred size range of 100 to 500 micrometers having a high loading of therapeutic agents.
- Coacervation is the term applied to the ability of a number of aqueous solutions of colloids, to separate into two liquid layers, one rich in colloid solute and the other poor in colloid solute. Factors which influence this liquid-liquid phase separation are: (a) the colloid concentration, (b) the solvent of the system, (c) the temperature, (d) the addition of another polyelectrolyte, and (e) the addition of a simple electrolyte to the solution. Coacervation can be of two general types.
- the first is called “simple” or “salt” coacervation where liquid phase separation occurs by the addition of a simple electrolyte to a colloidal solution.
- the second is termed “complex” coacervation where phase separation occurs by the addition of a second colloidal species to a first colloidal solution, the particles of the two dispersed colloids being oppositely charged.
- materials capable of exhibiting an electric charge in solution i.e. materials which possess an ionizable group are coacervable.
- Such materials include natural and synthetic macromolecular species such as gelatin, acacia, tragacanth, styrene-maleic anhydride copolymers, methyl vinyl ether-maleic anhydride copolymers, polymethacrylic acid, and the like.
- a water-immiscible material such as an oil
- a simple electrolyte such as sodium sulfate, or another, oppositely charged colloidal species
- the encapsulating colloidal material forms around each oil droplet, thus investing each of said droplets in a liquid coating of the coacervated colloid.
- the liquid coatings which surround the oil droplets must thereafter be hardened by cross-linking to produce solid-walled microcapsules
- the wound dressing according to any aspect of the present invention is sterile and packaged in a microorganism-impermeable container.
- a second aspect of the invention provides modified elastin as described in the first aspect of the invention.
- a third aspect of the invention provides a polynucleotide sequence encoding a modified tropoelastin polypeptide which polypeptide may be cross-linked with other such tropoelastin polypeptides to form the modified elastin of the second aspect of the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003299187A AU2003299187A1 (en) | 2002-10-01 | 2003-10-01 | Controlled release therapeutic wound dressings |
EP03756558A EP1545638A1 (en) | 2002-10-01 | 2003-10-01 | Controlled release therapeutic wound dressings |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0222723.9 | 2002-10-01 | ||
GB0222723A GB2393724B (en) | 2002-10-01 | 2002-10-01 | Controlled release therapeutic wound dressings |
US49333803P | 2003-08-08 | 2003-08-08 | |
US60/493,338 | 2003-08-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004030712A1 true WO2004030712A1 (en) | 2004-04-15 |
Family
ID=32071242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2003/004295 WO2004030712A1 (en) | 2002-10-01 | 2003-10-01 | Controlled release therapeutic wound dressings |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1545638A1 (en) |
AU (1) | AU2003299187A1 (en) |
WO (1) | WO2004030712A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001080921A2 (en) * | 2000-04-20 | 2001-11-01 | Emory University | Native protein mimetic fibers, fiber networks and fabrics for medical use |
WO2002053172A2 (en) * | 2000-12-29 | 2002-07-11 | Kimberly-Clark Worldwide, Inc. | Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover |
-
2003
- 2003-10-01 EP EP03756558A patent/EP1545638A1/en not_active Withdrawn
- 2003-10-01 WO PCT/GB2003/004295 patent/WO2004030712A1/en not_active Application Discontinuation
- 2003-10-01 AU AU2003299187A patent/AU2003299187A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001080921A2 (en) * | 2000-04-20 | 2001-11-01 | Emory University | Native protein mimetic fibers, fiber networks and fabrics for medical use |
WO2002053172A2 (en) * | 2000-12-29 | 2002-07-11 | Kimberly-Clark Worldwide, Inc. | Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover |
Non-Patent Citations (1)
Title |
---|
MECHAM R.P ET AL.: "Elastin degradation by matrix metalloproteinases", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 29, 1997, pages 18071 - 18076, XP002270620 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003299187A1 (en) | 2004-04-23 |
EP1545638A1 (en) | 2005-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7732655B2 (en) | Controlled release therapeutic wound dressings | |
EP1429702B1 (en) | Therapeutic wound dressings with exudate-dependent enlargement of apertures | |
EP1545637B1 (en) | Enzyme-sensitive therapeutic wound dressings | |
US8067370B2 (en) | Pain-sensitive therapeutic wound dressing | |
Laurano et al. | Wound dressing products: A translational investigation from the bench to the market | |
US7772454B2 (en) | Wound treatment device | |
GB2392836A (en) | Wound dressings for the treatment of wound infection | |
US10543293B2 (en) | Medical dressing | |
US7368128B2 (en) | Controlled release dressing for enzymatic debridement of necrotic and non-viable tissue in a wound | |
WO2004024196A1 (en) | Wound dressings for the treatment of wound infection | |
EP1545638A1 (en) | Controlled release therapeutic wound dressings | |
GB2393724A (en) | Controlled release therapeutic wound dressings | |
Lu et al. | A Comprehensive Exploration of Hydrogel Applications in Multi-Stage Skin Wound Healing | |
Choudhury et al. | Film: A Miscellaneous Drug Delivery with its Current Application in Diabetic Wound Healing | |
Braund et al. | Biomaterials as Platforms for Topical Administration of Therapeutic Agents in Cutaneous Wound Healing | |
GB2401041A (en) | Pain-sensitive therapeutic wound dressings | |
Shai et al. | Debridement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003756558 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003756558 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003756558 Country of ref document: EP |